Thermo Fisher Scientific, the world leader in serving science, recently announced that it will be investing more than $50m (¡ê39.8m) in its global bioproduction capabilities to provide additional capacity for manufacturing single-use bioprocess container (BPC) systems.
The company's single-use technologies are typically used by biopharma companies around the world for drug development.
Thermo Fisher will invest $12m (¡ê9.5m) expanding its GMP facility in Cramlington, adding assembly capacity and BPC systems manufacturing. The proximity of these capabilities to customers in Europe will shorten lead times and improve overall global efficiency.
"This year has been exceptional for us," Nicole Aspinall, site director, explains.
"The market is growing so rapidly and is expected to continue to grow by double figures for the foreseeable future. This year we have been expanding the teams across site to add the capacity we need to support our customers. The investment is great news for the site and the region too as we continue to expand our facility and grow the team.
"We are really proud of the products we are making here which are really making a difference to people lives. This year we implemented a night shift which has been really successful in getting up to speed with the growing demand in the market. In fact it has been so successful we are increasing this operation to expand our output."
There are several job vacancies currently advertised on the Thermo Fisher careers website, with more positions to be added in the near future.
